Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2017 Publisher: Bayer plc, 400 South Oak Way, Reading, RG2 6AD
Bonefos 800 mg tablets.
| Pharmaceutical Form |
|---|
|
Pale white, oval-shaped, film-coated tablets for oral use. |
Each tablet contains 1000 mg of disodium clodronate tetrahydrate, equivalent to 800 mg of anhydrous disodium clodronate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Clodronic acid |
Clodronic acid is a bisphosphonate, (formerly diphosphonates), a group of analogues of pyrophosphate, which have been shown, in vitro, to inhibit the formation and dissolution of calcium phosphate (hydroxyapatite). In vivo, they have been shown to inhibit bone resorption to a greater or lesser extent, depending on the compound, and clodronate is one of the most effective in this respect. |
| List of Excipients |
|---|
|
Croscarmellose sodium Coating: Opadry II white, containing: Macrogol (PEG) 3350 |
Bonefos tablets are supplied in clear, colourless PVC/aluminium blister packs of 10 and 60 tablets.
Not all pack sizes may be marketed.
Bayer plc, 400 South Oak Way, Reading, RG2 6AD
PL 00010/0522
01 May 2008
| Drug | Countries | |
|---|---|---|
| BONEFOS | Brazil, Finland, Hong Kong, Netherlands, Tunisia |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
